RxDoctor Payments Data

Steven Cohen, MD

Cardiovascular Disease · Delray Beach, FLNPI 1255353785

Payments from drug & device makers

$479,643in general payments, 2019–2025

Across 781 payments — averaging $614.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$366K
  • Merck$67K
  • Boston Scientific$19K
  • Abbott$7K
  • Pfizer$4K
  • Atricure, Inc.$2K
  • plus $14K from 54 others

What the payments were for

  • Consulting fees$6,1605%
  • Speaking & faculty fees$74,88559%
  • Travel & lodging$20,72116%
  • Food & beverage$24,69219%
  • Education$1760%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer189$365,913
Merck88$67,241
Boston Scientific58$18,863
Abbott37$6,684
Pfizer25$4,060
Atricure, Inc.12$2,412
AstraZeneca36$1,834
Medtronic(2 entities)21$1,670
Amgen(2 entities)55$1,330
Novo Nordisk29$1,083
Boehringer Ingelheim35$1,002
Edwards Lifesciences9$756
Johnson & Johnson15$690
Sanofi-aventis U.S. LLC8$494
Esperion Therapeutics, Inc.10$490
Bard Peripheral Vascular, Inc.15$399
Novartis21$371
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)14$356
Heartflow, Inc.3$337
Astellas Pharma US Inc3$290
Biosense Webster, Inc.5$247
Abiomed2$205
Regeneron Healthcare Solutions, Inc.3$202
Akcea Therapeutics, Inc.4$189
Biotronik Inc.3$187
Lilly USA, LLC5$177
E.r. Squibb & Sons, L.L.C.9$174
Sumitomo Pharma America, Inc.8$160
Sanofi2$149
Convatec Inc.1$143
Lundbeck LLC7$141
Impulse Dynamics (USA) Inc.2$126
Regeneron1$109
Alnylam Pharmaceuticals Inc.2$105
United Therapeutics Corporation1$100
Kowa Pharmaceuticals America, Inc.4$82
Amarin Pharma, Inc.3$66
BD1$58
Biohaven Pharmaceutical Holding Company Ltd.2$54
Smith+Nephew2$52
AbbVie3$50
Bridgebio Pharma, Inc.1$49
Exact Sciences2$44
Agepha Pharma FZ LLC2$41
G Medical Diagnostic Services, Inc.3$40
Irhythm Technologies, Inc.2$38
Braemar Manufacturing, LLC1$37
Philips North America LLC1$36
GSK2$30
Cvrx, Inc.1$29
Arbor Pharmaceuticals, Inc.2$28
Takeda Pharmaceuticals U.S.A., Inc.1$25
Corcept Therapeutics1$24
Azurity Pharmaceuticals, Inc.1$23
Vifor Pharma, Inc.1$23
Otsuka America Pharmaceutical, Inc.1$22
Bardy Diagnostics, Inc.1$20
Apellis Pharmaceuticals, Inc.1$19
Kiniksa Pharmaceuticals International, PLC1$19
Kestra Medical Technology Services, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$479,643 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$967,202
Medicare patients
1,337
Services billed
8,409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban205$263,083
JardianceEmpagliflozin152$185,592
EntrestoSacubitril/Valsartan100$159,113
XareltoRivaroxaban104$125,718
FarxigaDapagliflozin Propanediol70$90,185
OzempicSemaglutide54$76,726
Repatha SureclickEvolocumab57$62,891
NexlizetBempedoic Acid/Ezetimibe28$31,508
MultaqDronedarone Hcl19$28,780
VerquvoVericiguat12$21,817
VascepaIcosapent Ethyl30$19,053
Ezetimibe413$13,369
BrilintaTicagrelor14$12,244
EdarbyclorAzilsartan Med/Chlorthalidone23$8,918
Rosuvastatin Calcium597$8,684

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$4,060$263,083205 claims
Boehringer IngelheimJardiance$1,002$185,592152 claims
NovartisEntresto$371$159,113100 claims
Johnson & JohnsonXarelto$690$125,718104 claims
AstraZenecaFarxiga, Brilinta$1,834$102,42984 claims
Novo NordiskOzempic$1,083$76,72654 claims
Esperion Therapeutics, Inc.Nexlizet$490$31,50828 claims
Sanofi-aventis U.S. LLCMultaq$494$28,78019 claims
MerckVerquvo$67,241$21,81712 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$28$8,91823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Delray Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →